Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Biotechnology

Healthcare
$0.31 -0.58%

-$0.00 today

Market cap
$69.95M
Beta
2.82
P/E (TTM)
-1.3
EPS (TTM)
-$0.54
52W Low $0.53High $2.35

Volume 2.77M

Average 3.79M

Returns on capital

Tenaya Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-73.5%

avg -46.8%

ROIC

-69.4%

avg -63.8%

ROA

-61.7%

avg -55.4%

Analysis

ROA is currently the strongest return metric at -61.7% versus its period average of -55.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Faraz Ali

President, CEO & DirectorUSD 983.96K53539.78K0.32%

Whittemore G. Tingley

Chief Medical OfficerUSD 702.84K58——

Deepak Srivastava

Scientific Founder, Chairman of Scientific Advisory Board & DirectorUSD 90.5K59120.00K0.07%

Eric N. Olson

Scientific Founder & Member of Scientific Advisory Board————

Kee-Hong Kim

Chief Technology Officer—60——

Benoit G. Bruneau

Scientific Founder————

Bruce R. Conklin

Scientific Founder————

Saptarsi Haldar

Scientific Founder————

Sheng Ding

Scientific Founder————

Eric Hyllengren

CFO & Principal Accounting Officer—51——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 10, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

31

$5.04M

Net Transaction Value

−$5.04M

Net selling

Most Active

COLUMN GROUP III GP, LP

11 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 17, 26

Ali Faraz

Direct

Sell$4.1K
Aug 17, 26

Ali Faraz

Direct

Sell$2.8K
Aug 17, 26

Ali Faraz

Direct

Sell$3.6K
Aug 17, 26

Ali Faraz

Direct

Sell$5.3K
Aug 17, 26

Tingley Whittemore

Direct

Sell$1.2K
Aug 17, 26

Tingley Whittemore

Direct

Sell$1.2K
Aug 17, 26

Tingley Whittemore

Direct

Sell$1.3K
Aug 17, 26

Tingley Whittemore

Direct

Sell$1.6K
May 18, 26

Ali Faraz

Direct

Sell$2.7K
May 18, 26

Tingley Whittemore

Direct

Sell$2.5K

1–10 of 31

Summary

Insiders reported 0 buys worth $0.00 and 31 sells worth $5.04M over the last 12 months. That adds up to net selling of $5.04M. COLUMN GROUP III GP, LP was the most active insider with 11 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Tenaya Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about TNYA's management, answered from reported figures.

Who manages TNYA?

Tenaya Therapeutics, Inc. (TNYA) lists 10 active executives. The top listed executive is Deepak Srivastava, Scientific Founder, Chairman of Scientific Advisory Board & Director.

Are TNYA insiders buying or selling?

Recent insider activity shows net buying of $221.07M.